Lixin Guo, Fengsheng Tian, Li Liu, Mingwei Chen, Chengxia Jiang, Shuangqing Li, Cong Liu, Yawei Zhang, Jie Qin, Dongni Yu, Yicen Zong, Wei Dai
AIM: To evaluate the efficacy and safety of retagliptin in Chinese patients with type 2 diabetes (T2D) inadequately controlled with metformin. MATERIALS AND METHODS: This multicentre, phase 3 trial consisted of a 16-week, randomized, double-blind, placebo-controlled period, where patients with HbA1c levels between 7.5% and 11.0% were randomized to receive either once-daily (QD) retagliptin 100 mg (n = 87) or placebo (n = 87), both as an add-on to metformin...
April 11, 2024: Diabetes, Obesity & Metabolism